Published Research

PTX-2 in Fibrosis

Raghu G, van den Blink B, Hamblin MJ, et al. (2018) Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial JAMA. [Epub May 20]

Gibson, KF, Kass, DJ (2018) Editorial: Clinical Trials in Idiopathic Pulmonary Fibrosis in the “Posttreatment Era” JAMA. [Epub May 20]

van den Blink B, et al. (2016) Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. J. Eur Respir J. 2016 Feb 11. [Epub ahead of print]

Verna EC, et al. (2015) Novel association between serum pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. Epub ahead of print June 29.

Dillingh MR, et al. (2013) Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis. Pulm Pharmacol Ther. Feb 4. [Article ahead of press]

Santhiago MR, et al. (2011) Monocyte development inhibitor PRM-151 decreases corneal myofibroblast generation in rabbitsExperimental Eye Research. Sep 14.

Murray, et al. (2010) TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int J Biochem Cell Biol. Oct 28. [Epub ahead of print]

Moreira, et al. (2010) Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. J Allergy Clin Immunol. Epub Jul 29

Murray LA, et al. (2010) Serum amyloid P ameliorates radiation-induced oral mucositis and fibrosis. Fibrogenesis & Tissue Repair. 3:11.

Duffield JS and Lupher ML Jr. (2010) PRM-151 (recombinant human serum amyloid P/Pentraxin 2) for the treatment of fibrosis. Drug News & Perspectives. 23(5).

Murray LA, et al. (2010) Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One. Mar 12;5(3):e9683.

Castaño AP, Lin SL et al. (2009). Serum amyoid P inhibits fibrosis through FcγR-dependent monocyte-macrophage regulation in vivo. Science Trans Med. Nov 4 (epub).

Haudek SB, Trial J et al. (2008) Fc receptor engagement mediates differentiation of cardiac fibroblast precursor cells. Proc Natl Acad Sci. U S A. Jul 22;105(29):10179-84.

Shao DD, Suresh R et al. (2008). Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol. Jun;83(6):1323-33.

Naik-Mathuria B, Pilling D et al. (2008). Serum amyloid P inhibits dermal wound healing. Wound Repair Regen. Mar-Apr;16(2):266-73.

Pilling D, Roife D et al. (2007). Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol. 2007 Sep 15;179(6):4035-44.

Pilling, D., N. M. Tucker, et al. (2006). Aggregated IgG inhibits the differentiation of human fibrocytes. J Leukoc Biol. 79(6): 1242-51.

Haudek SB, Xia Y et al. (2006). Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci. U S A. Nov 28;103(48):18284-9.

Pilling, D., C. D. Buckley, et al. (2003). Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol171(10): 5537-46.

Monocyte-Derived Cells in Fibrosis

Mathai SK, et al. (2010) Circulating Monocytes from Systemic Sclerosis Patients with Interstitial Lung Disease Show an Enhanced Profibrotic Phenotype. Lab Invest. Jun;90(6):812-23. Epub 2010 Apr 19.

Moeller A, et al. (2009) Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 179(7): 588-94.

Lin SL, Castaño AP et al. (2009). Bone Marrow Ly6Chigh Monocytes Are Selectively Recruited to Injured Kidney and Differentiate into Functionally Distinct Populations. J Immunol. Oct 28 (epub).

Pilling D, Fan T et al. (2009) Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One. Oct 16;4(10):e7475.

Mehrad B et al. (2007) Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun. Feb 2;353(1):104-8. Epub 2006 Dec 11

Wang, J. F., H. Jiao, et al. (2007). Fibrocytes from burn patients regulate the activities of fibroblasts. Wound Repair Regen. 15(1): 113-21.

Cowper, S. E. and P. J. Boyer (2006). Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep. 8(2): 151-7.

Gaedeke, J., H. H. Neumayer, et al. (2006). Pharmacological management of renal fibrotic disease. Expert Opin Pharmacother. 7(4): 377-86.

Kisseleva, T., H. Uchinami, et al. (2006). Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol. 45(3): 429-38.

Lama, V. N. and S. H. Phan (2006). The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond. Proc Am Thorac Soc. 3(4): 373-6.

Lupher, M.L. and W.M. Galatin (2006). Regulation of Fibrosis by the Immune System. Adv Immunol. 89: 245-88.

Quan, T. E., S. E. Cowper, et al. (2006). The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep. 8(2): 145-50.

Varcoe, R. L., M. Mikhail, et al. (2006). The role of the fibrocyte in intimal hyperplasia. J Thromb Haemost. 4(5): 1125-33.

Garlanda, C., B. Bottazzi, et al. (2005). Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 23: 337-66.

Mori, L., A. Bellini, et al. (2005). Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res. 304(1): 81-90.

Canbay, A., S. Friedman, et al. (2004). Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39(2): 273-8.

Garantziotis, S., M. P. Steele, et al. (2004). Pulmonary fibrosis: thinking outside of the lung. J Clin Invest. 114(3): 319-21.

Gregory, C. D. and A. Devitt (2004). The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically? Immunology 113(1): 1-14.

Phillips, R. J., M. D. Burdick, et al. (2004). Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest. 114(3): 438-46.

Gordon, S. (2003). Alternative activation of macrophages. Nat Rev Immunol. 3(1): 23-35.

Chesney, J., C. Metz, et al. (1998). Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol. 160(1): 419-25.

General Fibrosis Reviews

Gomer RH and Lupher ML Jr. (2010) Investigational approaches to therapies for idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. Jun;19(6):737-45.

Lupher, M.L. and W.M. Galatin (2006). Regulation of Fibrosis by the Immune System. Adv Immunol. 89: 245-88.

Bataller, R. and D. A. Brenner (2005). Liver fibrosis. J Clin Invest. 115(2): 209-18.

Friedman, S. L. (2003). Liver fibrosis -- from bench to bedside. J Hepatol. 38 Suppl 1: S38-53.

Tomasek, J. J., G. Gabbiani, et al. (2002). Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 3(5): 349-63.

Pentraxin-2 mechanism of action
Pentraxin-2 therapeutics act as a master regulator of the complex fibrosis cascade, promoting healing and preventing disease progression. Learn More >